Homepage | Spatially targeted eradication of antimicrobial-resistant bacteria

What is the TARGET-THERAPY Project?

Focus

12 mars 2026 - 31 décembre 2030

Appel à projets

The Target‑Therapy project evolves into the PHOENIX project (FR/DE/IT)

Target‑Therapy continues with support from Inserm through the 2025 “Projet de recherche international” (PRI) call.

Key data

100%

Project progression

Ended on December 31, 2025

3

Research sites

- Univ Brest (FR)

- Univ Reims (FR)

- Univ Siegen (DE)

15

People

- Researchers

- Postdocs

- PhD students

731 108

Euros

Funded by:

- ANR (FR)

- BMBF (DE)

2nd French-German call for projects on antimicrobial resistance 2020 “One Health: AMR in environmental reservoirs and colonizing antibiotic resistant bacteria”

The specific objective of this project is to significantly improve the treatment of infections with the WHO priority-1 pathogen P. aeruginosa, which is one of the most dangerous key multi-drug resistant bacteria, inside biofilms in the lungs.

Affiliated institutions

Publication des premiers résultats de l'appel à projets générique 2018 | ANR

target-therapy